Guggenheim Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $90.00

AnaptysBio (NASDAQ:ANAB) had its price objective hoisted by Guggenheim from $75.00 to $90.00 in a report issued on Monday, Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on ANAB. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research report on Thursday, September 26th. Truist Financial boosted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

AnaptysBio Stock Performance

AnaptysBio stock opened at $32.22 on Monday. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $41.31. The firm has a market cap of $880.22 million, a PE ratio of -5.25 and a beta of -0.29. The firm’s 50 day moving average price is $35.49 and its two-hundred day moving average price is $29.65.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. Equities analysts anticipate that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insider Activity at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio in the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of AnaptysBio in the 1st quarter worth approximately $265,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of AnaptysBio during the 1st quarter worth approximately $1,221,000. Acadian Asset Management LLC bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $420,000. Finally, Platinum Investment Management Ltd. bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $1,490,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.